GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » Operating Income

Zimmer Biomet Holdings (Zimmer Biomet Holdings) Operating Income

: $1,452 Mil (TTM As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

Zimmer Biomet Holdings's Operating Income for the three months ended in Dec. 2023 was $421 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $1,452 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Zimmer Biomet Holdings's Operating Income for the three months ended in Dec. 2023 was $421 Mil. Zimmer Biomet Holdings's Revenue for the three months ended in Dec. 2023 was $1,940 Mil. Therefore, Zimmer Biomet Holdings's Operating Margin % for the quarter that ended in Dec. 2023 was 21.69%.

Good Sign:

Zimmer Biomet Holdings Inc operating margin is expanding. Margin expansion is usually a good sign.

Zimmer Biomet Holdings's 5-Year average Growth Rate for Operating Margin % was 5.90% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zimmer Biomet Holdings's annualized ROC % for the quarter that ended in Dec. 2023 was 12.39%. Zimmer Biomet Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 30.81%.


Zimmer Biomet Holdings Operating Income Historical Data

The historical data trend for Zimmer Biomet Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,269.80 704.70 1,005.40 1,192.10 1,451.30

Zimmer Biomet Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 326.80 370.50 362.00 298.20 420.80

Zimmer Biomet Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,452 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zimmer Biomet Holdings  (NYSE:ZBH) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zimmer Biomet Holdings's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=1683.2 * ( 1 - -47.52% )/( (20508.4 + 19564.5)/ 2 )
=2483.05664/20036.45
=12.39 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Zimmer Biomet Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1339.2/( ( (2032.2 + max(2363.4, 0)) + (2060.4 + max(2236.3, 0)) )/ 2 )
=1339.2/( ( 4395.6 + 4296.7 )/ 2 )
=1339.2/4346.15
=30.81 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1340.7 + 2323.3 + 415.9) - (416.8 + 0 + 1299.7)
=2363.4

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1442.4 + 2385.2 + 366.1) - (1516.6 + 0 + 440.8)
=2236.3

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Zimmer Biomet Holdings's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=420.8/1940.1
=21.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Zimmer Biomet Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Traded in Other Exchanges
Address
345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Executives
Syed A. Jafry director 345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli director C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley director
Robert Hagemann director 3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson director 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard director 711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps officer: Assoc. Gen. Counsel, Corp. Sec C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van officer: Pres, Europe, M. East & Africa 345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato officer: VP, Controller & CAO C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi officer: President, Asia Pacific 345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler officer: SVP and CHRO 345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson officer: SVP & CSO 345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson director, officer: President and CEO ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau officer: Group President 345 E. MAIN STREET, WARSAW IN 46580